Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 555,038
  • Shares Outstanding, K 125,859
  • Annual Sales, $ 0 K
  • Annual Income, $ -110,780 K
  • EBIT $ -112 M
  • EBITDA $ -104 M
  • 60-Month Beta 1.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 156.44% ( +7.30%)
  • Historical Volatility 84.29%
  • IV Percentile 86%
  • IV Rank 68.03%
  • IV High 222.96% on 03/25/24
  • IV Low 14.89% on 12/06/23
  • Put/Call Vol Ratio 0.21
  • Today's Volume 1,132
  • Volume Avg (30-Day) 4,046
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 84,160
  • Open Int (30-Day) 80,211

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.24
  • Number of Estimates 2
  • High Estimate -0.22
  • Low Estimate -0.26
  • Prior Year -0.24
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.15 +9.03%
on 11/19/24
6.11 -25.95%
on 11/08/24
-0.82 (-15.27%)
since 10/21/24
3-Month
4.15 +9.03%
on 11/19/24
7.48 -39.51%
on 08/26/24
-1.95 (-30.07%)
since 08/21/24
52-Week
2.43 +86.20%
on 11/27/23
9.97 -54.62%
on 05/31/24
+2.08 (+85.43%)
since 11/21/23

Most Recent Stories

More News
Humacyte Clinical Results Highlighting Benefit of the ATEVâ„¢ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery

HUMA : 4.53 (+2.72%)
Insider Sale: President of $HUMA (HUMA) Sells 427,459 Shares

Laura E Niklason, the President of $HUMA ($HUMA), sold 427,459 shares of the company on 11-19-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 17.7% of their...

HUMA : 4.53 (+2.72%)
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024

HUMA : 4.53 (+2.72%)
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

HUMA : 4.53 (+2.72%)
Humacyte’s (HUMA) Lab-Grown Vessels Await FDA Approval for Vascular Trauma Use

Humacyte (HUMA) is advancing the field of regenerative medicine with its lab-grown blood vessels, known as acellular tissue-engineered vessels (ATEVs), poised to transform treatment options for patients...

HUMA : 4.53 (+2.72%)
Humacyte Third Quarter 2024 Financial Results and Business Update

HUMA : 4.53 (+2.72%)
Humacyte (HUMA) Faces Key Regulatory Hurdles Ahead of Q3 Earnings

Humacyte (HUMA), a clinical-stage biotech firm developing implantable human tissue, is set to announce its third-quarter financial results on November 8, 2024. The company, known for its acellular tissue-engineered...

HUMA : 4.53 (+2.72%)
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024

HUMA : 4.53 (+2.72%)
Humacyte (HUMA) Faces Regulatory Scrutiny as FDA Raises Quality Concerns

Humacyte (HUMA) experienced a decline of 1.94% in its latest trading session, closing at $5.05, which was slightly more than the S&P 500's 1.86% daily loss. Over the past month, Humacyte's shares have...

HUMA : 4.53 (+2.72%)
Insider Sale: Director at Humacyte (HUMA) Sells 1,548 Shares

Kathleen Sebelius, a director at Humacyte ($HUMA), sold 1,548 shares of the company on 09-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.6% of their...

HUMA : 4.53 (+2.72%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 4.84
2nd Resistance Point 4.71
1st Resistance Point 4.56
Last Price 4.53
1st Support Level 4.28
2nd Support Level 4.14
3rd Support Level 3.99

See More

52-Week High 9.97
Fibonacci 61.8% 7.09
Fibonacci 50% 6.20
Fibonacci 38.2% 5.31
Last Price 4.53
52-Week Low 2.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar